Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Grady Memorial Hospital, Atlanta, GA, USA.
Meridian HealthComms, Plumley Moor Road, Plumley, UK.
J Crit Care. 2019 Apr;50:144-154. doi: 10.1016/j.jcrc.2018.11.031. Epub 2018 Nov 30.
Guidelines recommend crystalloids for fluid resuscitation in sepsis/shock and switching to albumin in cases where crystalloids are insufficient. We evaluated hemodynamic response to crystalloids/colloids in critically ill adults.
The primary research question was: "Are crystalloids sufficient for volume replacement in severe indications (intensive care unit [ICU]/critical illness)?" Randomized, controlled trials (RCTs) were identified using PubMed and EMBASE, and screened against predefined inclusion/exclusion criteria. Meta-analyses were performed on extracted data.
Fifty-five RCTs (N = 27,036 patients) were eligible. Central venous pressure was significantly lower with crystalloids than with albumin, hydroxyethyl starch (HES), or gelatin (all p < .001). Mean arterial pressure was significantly lower with crystalloids vs. albumin (mean difference [MD]: -3.5 mm Hg; p = .03) or gelatin (MD: -9.2 mm Hg; p = .02). Significantly higher volumes of crystalloids were administered vs. HES (MD: +1775 mL); volume administered was numerically higher vs. albumin (MD: +1985 mL). Compared with the albumin group, cardiac index was significantly lower in the crystalloid group (MD: -0.6 L/min/m, p < .001). All mortality and 90-day mortality were significantly lower for crystalloids compared with HES (relative risk 0.91; p = .009 and 0.9; p = .005, respectively).
Crystalloids were less efficient than colloids at stabilizing resuscitation endpoints; guidance on when to switch is urgently required.
指南建议在脓毒症/休克中使用晶体液进行液体复苏,并在晶体液不足的情况下改用白蛋白。我们评估了危重症成人对晶体液/胶体液的血流动力学反应。
主要研究问题是:“在严重情况下(重症监护病房[ICU]/危重病),晶体液是否足以替代容量?” 使用 PubMed 和 EMBASE 确定了随机对照试验(RCT),并根据预设的纳入/排除标准进行了筛选。对提取的数据进行了荟萃分析。
符合条件的 RCT 有 55 项(N=27036 名患者)。与白蛋白、羟乙基淀粉(HES)或明胶相比,晶体液的中心静脉压明显更低(均 p<0.001)。与白蛋白相比,晶体液的平均动脉压明显更低(平均差异[MD]:-3.5mmHg;p=0.03)或明胶(MD:-9.2mmHg;p=0.02)。与 HES 相比,晶体液的给药量明显更高(MD:+1775mL);与白蛋白相比,给药量数值更高(MD:+1985mL)。与白蛋白组相比,晶体液组的心指数明显更低(MD:-0.6L/min/m,p<0.001)。与 HES 相比,所有死亡率和 90 天死亡率均明显更低(相对风险 0.91;p=0.009 和 0.9;p=0.005)。
晶体液在稳定复苏终点方面的效率低于胶体液;迫切需要指导何时切换。